RXi Pharmaceuticals CEO to Present a Session Keynote at IBC's Oligonucleotide Therapeutics Conference...
WORCESTER, Mass.--Mass., Jul 28, 2009 (BUSINESS WIRE) -- RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company's President and CEO, Tod Woolf, Ph.D., will deliver a session keynote presentation at IBC's Oligonucleotide Therapeutics - From Concept to Creation Conference, which is part of Drug Discovery and Development Week, taking place August 3-6, 2009 in Boston, MA.
RNA interference (RNAi) technology has been heralded as a major breakthrough in science with the potential to block the expression of disease-causing genes. Dr. Woolf's keynote "Thirty Years of Targeting RNA: A Retrospective" will explore the great variety of therapeutic oligonucleotide properties and how these characteristics provided insight on designing compounds with "self-delivery" properties, or delivery to cells and tissues without the use of a separate delivery vehicle. His presentation will begin at 9:10 am on Monday, August 3, 2009.
Dr. Woolf will also participate in a CEO panel discussion on RNA therapeutics that brings together leaders in the RNAi field to discuss the current and potential states of development, as well as how companies are capitalizing on the promise of this new class of drugs. The session will be held from 11:50 to 12:30 on Tuesday August 4, 2009. Furthermore, Dr. Woolf will serve as a panelist in a roundtable discussion on the intellectual property landscape in RNAi therapeutics at 4:15 on August 3, 2009.
In addition to the Keynote address and the CEO panel discussion by Dr. Woolf, the conference also includes a presentation by RXi's Vice President of Technology Development, Dmitry Samarsky, Ph.D., on the "Development of Novel RNAi Therapeutic Compounds and In Vivo Delivery Approaches," as well as a presentation by one of RXi's collaborators, Gary Ostroff, Ph.D., using a technology platform licensed by RXi, the Glucan Encapsulated RNAi Particle (GeRP) delivery system.
IBC's Drug Discovery and Development Week, to be held at the World Trade Center in Boston, MA, expects more than 3,000 pharmaceutical, biotechnology, government and academic researchers, executives, and technology providers to participate. The five targeted scientific conferences at this event focus on practical strategies and forward-looking approaches to help accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.
About RNA Interference (RNAi)
Regarded as a revolutionary discovery in biology, RNA interference (RNAi) is a naturally occurring mechanism whereby short, double-stranded RNA molecules interfere with the expression of genes in living cells. This mechanism has the potential to be harnessed to "silence" or specifically block the production of disease-causing proteins before they are made. This technology can potentially be used to treat human diseases by "turning-off" genes that lead to disease in the first place. RXi Pharmaceuticals is using RNAi technology to develop RNA-derived molecules targeting disease-causing genes.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and delivery methods. RXi uses its own version of RNAi compounds -- rxRNAT -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. rxRNAT compounds are designed specifically for therapeutic use and contain many of the properties needed to move RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. www.rxipharma.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, risks related to development and commercialization of products by our competitors, risks related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
SOURCE: RXi Pharmaceuticals
RXi Pharmaceuticals
Donna Falcetti, 508-929-3615
ir@rxipharma.com
or
Investors
SAN Group
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com
